Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group (Q43196809)

From Wikidata

Jump to navigation Jump to search

scientific article published in March 2010

Language	Label	Description	Also known as
English	Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group	scientific article published in March 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Atae Utsunomiya

21

object named as

Atae Utsunomiya

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

5

object named as

Naokuni Uike

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

author name string

Ritsuko Seki

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Koichi Ohshima

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Koji Nagafuji

3

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Tomoaki Fujisaki

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Fumio Kawano

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Hisashi Gondo

7

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Shigeyoshi Makino

8

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Tetsuya Eto

9

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Yukiyoshi Moriuchi

10

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Fumihiro Taguchi

11

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Tomohiko Kamimura

12

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Hiroyuki Tsuda

13

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Ryosuke Ogawa

14

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Kazuya Shimoda

15

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Kiyoshi Yamashita

16

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Keiko Suzuki

17

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Hitoshi Suzushima

18

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Kunihiro Tsukazaki

19

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Masakazu Higuchi

20

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Masahiro Iwahashi

22

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Yutaka Imamura

23

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Kazuo Tamura

24

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Junji Suzumiya

25

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Minoru Yoshida

26

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Yasunobu Abe

27

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Tadashi Matsumoto

28

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Takashi Okamura

29

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

publication date

1 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

91

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

258-266

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

https://scigraph.springernature.com/pub.10.1007/s12185-009-0475-2

0 references

Practical utility of the revised European-American classification of lymphoid neoplasms for Japanese non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1007%2FS12185-009-0475-2

21 January 2018

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS12185-009-0475-2

21 January 2018

Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-009-0475-2

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diffuse aggressive lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic biomarkers in diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer incidence and incidence rates in Japan in 1995: estimates based on data from nine population-based cancer registries. The Research Group for Population-based Cancer Registration in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20066574

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-009-0475-2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43196809&oldid=1983610898"